Gene · 259197
Papers4,252
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 4,252
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma. | J Gynecol Oncol | 2024 | 38606823 | PubTator, text mining | PubMed |
Effects of Reishimmune-S, a Fungal Immunomodulatory Peptide Supplement, on the Quality of Life and Circulating Natural Killer Cell Profiles of Patients With Early Breast Cancer Receiving Adjuvant Endocrine Therapy. | Integr Cancer Ther | 2024 | 38590244 | PubTator, text mining | PubMed |
| NK cell receptor profiling of endometrial and decidual NK cells reveals pregnancy-induced adaptations. | Front Immunol | 2024 | 38571943 | PubTator, text mining | PubMed |
| Aberrant phenotypes of circulating γδ-T cells may be involved in the onset of systemic lupus erythematosus. | Lupus | 2024 | 38506324 | PubTator, text mining | PubMed |
| CTLA-4 Blockade of Natural Killer Cells Increases Cytotoxicity against Acute Lymphoid Leukaemia Cells Neda. | Cell J | 2024 | 38459732 | PubTator, text mining | PubMed |
| CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells. | Blood | 2024 | 38437507 | PubTator, text mining | PubMed |
| Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers. | MAbs | 2024 | 38372053 | PubTator, text mining | PubMed |
| Roles of innate lymphoid cells in metabolic and alcohol-associated liver diseases. | JHEP Rep | 2024 | 38304237 | PubTator, text mining | PubMed |
| Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma. | Discov Oncol | 2024 | 38294629 | PubTator, text mining | PubMed |
| Tumorous IRE1α facilitates CD8+T cells-dependent anti-tumor immunity and improves immunotherapy efficacy in melanoma. | Cell Commun Signal | 2024 | 38291473 | PubTator, text mining | PubMed |
| Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity. | Immun Inflamm Dis | 2024 | 38270321 | PubTator, text mining | PubMed |
| A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma. | Eur J Med Res | 2024 | 38268058 | PubTator, text mining | PubMed |
| Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer. | BMC Cancer | 2024 | 38263004 | PubTator, text mining | PubMed |
| Extracellular Vesicles and Exosomes: Novel Insights and Perspectives on Lung Cancer from Early Detection to Targeted Treatment. | Biomedicines | 2024 | 38255228 | PubTator, text mining | PubMed |
| Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit. | Cancers (Basel) | 2024 | 38254801 | PubTator, text mining | PubMed |
| The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. | Cell Commun Signal | 2024 | 38254135 | PubTator, text mining | PubMed |
High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor. | J Exp Clin Cancer Res | 2024 | 38245792 | PubTator, text mining | PubMed |
| Breakthrough of solid tumor treatment: CAR-NK immunotherapy. | Cell Death Discov | 2024 | 38245520 | PubTator, text mining | PubMed |
| Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells. | Immunohorizons | 2024 | 38240638 | PubTator, text mining | PubMed |
| Harnessing natural killer cell effector function against cancer. | Immunother Adv | 2024 | 38223411 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/259197/papers?page=10